Raf inhibitors

US8232283B2 · kind B2 · utility

Assignee

• FORMA Therapeutics, Inc. · US

Inventors

• Andreas Schoop · Overath, DE
• Alexander Backes · Munich, DE
• Joachim Vogt · Munich, DE
• Lars Neumann · Kottgeisering, DE
• Jan Eickhoff · Herdecke, DE
• Stefan Hannus · Munich, DE
• Kerrin Hansen · Gilching, DE
• Peter Amon · Gilching, DE
• Igor Ivanov · Markt Indersdorf, DE
• Matthias Borgmann · Rödental, DE
• Chase C. Smith · Rutland, US
• Arthur F. Kluge · Lincoln, US
• Krishan Murthi · Andover, US
• Rebecca Casaubon · Cambridge, US

Key dates

• Filing date: May 12, 2011
• Grant date: Jul 31, 2012
• Expiry date: May 12, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.